rs1160351 - MDGA2

Magnitude 4.5 · 1 study on file

Reported associations

• Genome-wide association study of SSRI/SNRI-induced sexual dysfunction in a Japanese cohort with major depression. - Psychiatry research (2013) · Kurose K, Hiratsuka K, Ishiwata K, Nishikawa J, Nonen S, Azuma J, Kato M, Wakeno M, Okugawa G, Kinoshita T, Kurosawa T, Hasegawa R, Saito Y · PubMed 22445761

  Sexual dysfunction is a major side effect of selective serotonin reuptake inhibitors (SSRIs) and serotonin-noradrenaline reuptake inhibitors (SNRIs). We conducted a genome-wide association study to identify the genetic factors contributing to the risk of SSRI/SNRI-induced sexual dysfunction by testing 186 320 single nucleotide polymorphism (SNP) markers in a cohort of 201 Japanese major depression patients including 36 with sexual dysfunction induced by SSRI (paroxetine or fluvoxamine) or SNRI (milnacipran). The Cochran-Armitage trend test showed that 11 SNPs, tightly clustered in a distinct region on chromosome 14q21.3, were associated with SSRI/SNRI-induced sexual dysfunction at a genome-wide significance level after false discovery rate (FDR) correction, and the strongest SNP associatio

Auto-generated from study metadata. AI-synthesised commentary is added when this entry is regenerated through content-service's LLM mode.